LDE225 --- Hedgehog Antagonist
| Overview | |
| Catalog # | bs-60013c-2mg-solid |
| Product Name | LDE225 --- Hedgehog Antagonist |
| Specifications | |
| Storage Buffer | Powder |
| Storage Condition | Store in dry, dark place at -20C for 1 year. |
| Target | |
| Product Information | Molecular Weight: 485.5 Formula: C26 H26 F3 N3 O3 CAS Number: 956697-53-3 InChi Key: VZZJRYRQSPEMTK-CALCHBBNSA-N InChi: InChI=1S/C26H26F3N3O3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13,16-17H,14-15H2,1-3H3,(H,31,33)/t16-,17+ Smiles: CC1C(=CC=CC=1C1C=CC(=CC=1)OC(F)(F)F)C(=O)NC1C=NC(=CC=1)N1C[C@H](C)O[C@H](C)C1 Purity: 98.0 Solubility: DMSO up to 100 mM Appearance: Solid Power Shelf Life: 1.0 years |
| Description | LDE225 is a potent and specific Hedgehog pathway inhibitor through binding and antagonizing Smo with an IC50 of 11 nM. It is currently in the clinical trials to treat cancers. It inhibited Hh signaling and induces tumor regression in animal models of medulloblastoma. It sensitized chemotherapy-resistant ovarian cancer cell lines to paclitaxel, but not to carboplatin. In one of the clinical trials, treatment with 0.75% LDE225 cream in NBCCS patients was very well tolerated and caused BCC regression. |
Powered by Bioz